Literature DB >> 8683291

Technetium-99m-sestamibi uptake in myeloma.

B K Adams1, A Fataar, M A Nizami.   

Abstract

A number of reports describe how 99mTc-sestamibi detects benign and malignant primary and metastatic tumors. We report abnormal 99mTc-sestamibi uptake in nine sites in a 53-yr-old patient with histologically and biochemically proven IgG kappa-secreting myeloma. The 99mTc-sestamibi study was undertaken for an unrelated hyperparathyroidism.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8683291

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  4 in total

1.  A potential artifact to consider when performing 99mTc-sestamibi myocardial perfusion SPECT imaging in patients with multiple myeloma.

Authors:  Yaser Baghdadi; Mario T Di Dea; Renée M Moadel; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2021-02-19       Impact factor: 5.952

Review 2.  Current and future imaging modalities for multiple myeloma and its precursor states.

Authors:  Esther Tan; Brendan M Weiss; Esther Mena; Neha Korde; Peter L Choyke; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2011-06-08

Review 3.  Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.

Authors:  Sigurdur Y Kristinsson; Alex R Minter; Neha Korde; Esther Tan; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2011-07       Impact factor: 5.225

4.  Limitations of Tc99m-MIBI-SPECT imaging scans in persistent primary hyperparathyroidism.

Authors:  Janneke E Witteveen; Job Kievit; Marcel P M Stokkel; Hans Morreau; Johannes A Romijn; Neveen A T Hamdy
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.